Hepatocellular carcinoma arising within a β-catenin mutated inflammatory hepatic adenoma

by Christopher M. Chandler, Kevin P. Labadie, James O. Park, Camtu D. Truong
Published 2021-06-01

Standardization of perioperative care facilitates safe discharge by postoperative day five after pancreaticoduodenectomy.

by Sara K Daniel, Lucas W Thornblade, Gary N Mann, James O Park, Venu G Pillarisetty
Published 2018-01-01

Cavernous hemangioma with extensive sclerosis masquerading as intrahepatic cholangiocarcinoma — A pathologist's perspective

by Nicole K. Andeen, MD, Puneet Bhargava, MD, James O. Park, MD, Mariam Moshiri, MD, Maria Westerhoff, MD
Published 2014-01-01

Glypican-3 Targeting of Liver Cancer Cells Using Multifunctional Nanoparticles

by James O. Park, Zachary Stephen, Conroy Sun, Omid Veiseh, Forrest M. Kievit, Chen Fang, Matthew Leung, Hyejung Mok, Miqin Zhang
Published 2011-01-01

Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma

by Andrew D. Ludwig, Kevin P. Labadie, Y. David Seo, Donald K. Hamlin, Holly M. Nguyen, Vimukta M. Mahadev, Raymond S. Yeung, D. S. Wilbur, James O. Park
Published 2019-01-01

Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma

by Kevin P. Labadie, Andrew D. Ludwig, Adrienne L. Lehnert, Donald K. Hamlin, Aimee L. Kenoyer, Kevin M. Sullivan, Sara K. Daniel, Tara N. Mihailovic, Jonathan G. Sham, Johnnie J. Orozco, Raymond S. Yeung, Delphine L. Chen, D. Scott Wilbur, Robert S. Miyaoka, James O. Park
Published 2021-02-01